.png){kind=icon}
.png){kind=icon}
Return
Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium
.png){kind=icon}
OA
AI
C
M
G
P
T
N
D
D
I
D
K
J
D
G
R
J
J
P
DOI：10.1002/ijc.70592.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late-stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high-grade precursors before clinical symptoms arise in patients at elevated risk of PDAC development. Classical imaging-based surveillance strategies, aligned with current guidelines, form the foundation of screening high-risk individuals, while organ-specific fluid analyses—such as cyst fluid and pancreatic juice—offer promising complementary tools with enhanced specificity. Recent advances in radiomics, liquid biopsy, microbiome, and multi-omics profiling are expanding the frontier of early detection. Despite advances, significant challenges persist. Precursor lesions are difficult to non-invasively diagnose; are not radiologically or endosonographically visible, or cannot be definitively graded prior to resection. Though biomarkers show promise for early detection, they present unique challenges: early-stage neoplasias release low levels of many biomarkers and thresholds for these biomarkers that define malignant transformation—and thus guide surgical intervention—remain poorly established. Multi-institutional initiatives like the Pancreatic Cancer Early Detection consortium (PRECEDE) are critical to bridging discovery and clinical translation. Our international cohort study of high-risk individuals was designed to discover and validate diagnostic biomarkers according to the PROBE study design. Continued collaboration, technological integration, and patient-centered approaches are essential to transform early detection research into tangible survival benefits for those at risk of PDAC.
Keywords:
biomarkers
early detection
imaging
liquid biopsy
pancreatic cancer
screening
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.7
Papers:
2.0W
Citations:
4.9W
Organization
Cited Papers